Scouting for GI disease assets for in-licensing

Challenge: A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and...
Learn More

Developing a revenue model for an AI application for GI Imaging

Challenge: Our client was a medical solutions provider specialising in AI applications applied to real-time analysis of medical imagery to provide clinicians with real-time decision-making...
Learn More

Triage DD of short bowel syndrome assets

Challenge: For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three...
Learn More

Due diligence on a AI-driven drug discovery platform

Challenge: A biotech company had developed an AI-driven drug discovery platform to discover phytocompounds and bioactives with the potential to impact human health. Alacrita was retained to conduct a...
Learn More

Assessing the BD landscape for in-licensing & acquisition deals in GI

Challenge: A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be...
Learn More

Value proposition and pricing for novel GI treatment

Challenge: A clinical stage pharma company with development and commercialization rights to a novel treatment for GI indications wanted to gain marketing authorization in Europe. However, the...
Learn More
1